PriceTargets.com logo

89bio - ETNB Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $30.33
  • Forecasted Upside: 282.03%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 4 Buy Ratings
  • 1 Strong Buy Ratings
$7.94 As of 12/20/2024 06:31 PM ET
▲ +0.91 (12.94%)

This chart shows the closing price for ETNB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New 89bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ETNB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ETNB

Analyst Price Target is $30.33
▲ +282.03% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for 89bio in the last 3 months. The average price target is $30.33, with a high forecast of $49.00 and a low forecast of $12.00. The average price target represents a 282.03% upside from the last price of $7.94.

This chart shows the closing price for ETNB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 7 investment analysts is to moderate buy stock in 89bio. This rating has held steady since September 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/12/2024Raymond JamesUpgradeStrong-Buy
11/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
11/8/2024Raymond JamesLower TargetStrong-Buy ➝ Strong-Buy$53.00 ➝ $49.00
9/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$29.00 ➝ $29.00
8/6/2024Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$50.00 ➝ $53.00
8/6/2024Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$13.00 ➝ $12.00
8/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
7/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$29.00 ➝ $29.00
6/12/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$29.00 ➝ $29.00
6/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
5/17/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$29.00
5/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$29.00
5/15/2024Evercore ISILower TargetOutperform ➝ Outperform$37.00 ➝ $33.00
5/10/2024HC WainwrightLower TargetBuy ➝ Buy$31.00 ➝ $29.00
4/22/2024Bank of AmericaReiterated RatingBuy$30.00
4/5/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$29.00
3/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$31.00
3/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$31.00
3/6/2024Evercore ISIBoost TargetOutperform ➝ Outperform$29.00 ➝ $37.00
3/5/2024OppenheimerReiterated RatingMarket Perform ➝ Market Perform
3/4/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$29.00
3/1/2024Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$15.00 ➝ $14.00
3/1/2024HC WainwrightLower TargetBuy ➝ Buy$32.00 ➝ $31.00
1/12/2024Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$24.00 ➝ $15.00
12/20/2023HC WainwrightLower TargetBuy ➝ Buy$35.00 ➝ $32.00
12/5/2023HC WainwrightReiterated RatingBuy ➝ Buy$35.00
11/28/2023HC WainwrightReiterated RatingBuy ➝ Buy$35.00
11/9/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$27.00 ➝ $24.00
10/12/2023UBS GroupLower TargetBuy ➝ Buy$36.00 ➝ $25.00
10/11/2023Evercore ISILower Target$49.00 ➝ $29.00
10/10/2023OppenheimerDowngradeOutperform ➝ Market Perform
10/10/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$34.00 ➝ $27.00
9/22/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$34.00
8/28/2023UBS GroupInitiated CoverageBuy$36.00
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$35.00
8/10/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$33.00 ➝ $34.00
8/10/2023Cantor FitzgeraldLower TargetOverweight ➝ Overweight$41.00 ➝ $39.00
7/2/2023BTIG ResearchBoost Target$30.00 ➝ $37.00
6/13/2023Evercore ISIInitiated CoverageOutperform$49.00
5/8/2023HC WainwrightBoost Target$30.00 ➝ $35.00
5/5/2023Cantor FitzgeraldBoost Target$40.00 ➝ $41.00
3/26/2023Bank of AmericaBoost Target$17.00 ➝ $24.00
3/22/2023OppenheimerBoost Target$18.00 ➝ $33.00
3/22/2023HC WainwrightBoost Target$25.00 ➝ $30.00
3/22/2023Royal Bank of CanadaBoost TargetOutperform$27.00 ➝ $36.00
3/22/2023Raymond JamesBoost Target$25.00 ➝ $50.00
3/22/2023Cantor FitzgeraldBoost Target$34.00 ➝ $45.00
3/14/2023Royal Bank of CanadaReiterated RatingOutperform$27.00
3/6/2023Cantor FitzgeraldReiterated RatingOverweight$34.00
2/21/2023OppenheimerBoost TargetOutperform$12.00 ➝ $18.00
2/7/2023HC WainwrightReiterated RatingBuy$27.00
11/14/2022Cantor FitzgeraldReiterated RatingOverweight$27.00 ➝ $34.00
11/11/2022Royal Bank of CanadaLower TargetOutperform$35.00 ➝ $29.00
9/14/2022Raymond JamesBoost TargetStrong-Buy$14.00 ➝ $25.00
8/17/2022HC WainwrightBoost TargetBuy$26.00 ➝ $27.00
7/27/2022HC WainwrightLower TargetBuy$29.00 ➝ $26.00
7/11/2022Leerink PartnersLower TargetOutperform$50.00 ➝ $29.00
6/30/2022OppenheimerLower TargetOutperform$40.00 ➝ $15.00
6/29/2022Raymond JamesBoost TargetStrong-Buy$12.00 ➝ $14.00
6/29/2022Royal Bank of CanadaBoost Target$35.00
6/29/2022BTIG ResearchLower TargetBuy$28.00 ➝ $24.00
5/17/2022Piper SandlerLower TargetOverweight$54.00 ➝ $19.00
5/13/2022OppenheimerLower Target$49.00 ➝ $40.00
5/12/2022HC WainwrightLower Target$46.00 ➝ $29.00
5/12/2022Cantor FitzgeraldLower Target$41.00 ➝ $27.00
5/12/2022Raymond JamesUpgradeOutperform ➝ Strong-Buy$33.00 ➝ $12.00
3/25/2022Leerink PartnersLower TargetOutperform$62.00 ➝ $50.00
12/20/2021HC WainwrightInitiated CoverageBuy$46.00
11/12/2021Royal Bank of CanadaLower TargetOutperform$46.00 ➝ $42.00
10/26/2021Cantor FitzgeraldReiterated RatingOverweight$58.00 ➝ $49.00
10/18/2021Cantor FitzgeraldReiterated RatingOverweight
8/15/2021Leerink PartnersReiterated RatingBuy$62.00
8/13/2021Royal Bank of CanadaLower TargetOutperform$48.00 ➝ $46.00
8/13/2021Raymond JamesLower TargetOutperform$35.00 ➝ $33.00
7/29/2021BTIG ResearchInitiated CoverageBuy$60.00
6/13/2021Leerink PartnersReiterated RatingBuy
5/25/2021Raymond JamesDowngradeStrong-Buy ➝ Outperform$65.00 ➝ $35.00
5/19/2021Leerink PartnersReiterated RatingBuy$62.00
4/21/2021Cantor FitzgeraldInitiated CoverageOverweight$58.00
3/25/2021Chardan CapitalBoost TargetBuy$92.00 ➝ $95.00
3/23/2021Leerink PartnersBoost TargetOutperform$56.00 ➝ $62.00
3/18/2021OppenheimerReiterated RatingBuy$60.00
11/11/2020Leerink PartnersBoost TargetOutperform$51.00 ➝ $56.00
10/19/2020Raymond JamesInitiated CoverageStrong-Buy$65.00
9/25/2020Bank of AmericaUpgradeNeutral ➝ Buy$43.00
9/15/2020BTIG ResearchBoost TargetBuy$51.00 ➝ $58.00
9/15/2020Chardan CapitalBoost TargetBuy$59.00 ➝ $95.00
8/13/2020Chardan CapitalBoost TargetBuy$58.00 ➝ $59.00
7/30/2020Piper SandlerInitiated CoverageOverweight$54.00
7/23/2020BTIG ResearchInitiated CoverageBuy
7/7/2020Chardan CapitalInitiated CoverageBuy$58.00
5/19/2020OppenheimerReiterated RatingBuy$60.00
1/2/2020Leerink PartnersReiterated RatingOutperform
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.15 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 8 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 7 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 6 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 6 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 18 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 18 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

89bio logo
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $7.94
Low: $6.60
High: $7.95

50 Day Range

MA: $8.45
Low: $7.03
High: $10.45

52 Week Range

Now: $7.94
Low: $6.43
High: $16.63

Volume

4,504,668 shs

Average Volume

980,337 shs

Market Capitalization

$842.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12

Frequently Asked Questions

What sell-side analysts currently cover shares of 89bio?

The following Wall Street research analysts have issued stock ratings on 89bio in the last twelve months: Bank of America Co., Cantor Fitzgerald, Evercore ISI, HC Wainwright, Oppenheimer Holdings Inc., Raymond James, and Royal Bank of Canada.
View the latest analyst ratings for ETNB.

What is the current price target for 89bio?

0 Wall Street analysts have set twelve-month price targets for 89bio in the last year. Their average twelve-month price target is $30.33, suggesting a possible upside of 282.0%. Raymond James has the highest price target set, predicting ETNB will reach $49.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $12.00 for 89bio in the next year.
View the latest price targets for ETNB.

What is the current consensus analyst rating for 89bio?

89bio currently has 2 hold ratings, 4 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ETNB.

What other companies compete with 89bio?

Other companies that are similar to 89bio include Janux Therapeutics, Edgewise Therapeutics, Xenon Pharmaceuticals, Merus and Twist Bioscience. Learn More about companies similar to 89bio.

How do I contact 89bio's investor relations team?

89bio's physical mailing address is 142 SANSOME STREET SECOND FLOOR, SAN FRANCISCO CA, 94104. The company's listed phone number is 415-432-9270 and its investor relations email address is [email protected]. The official website for 89bio is www.89bio.com. Learn More about contacing 89bio investor relations.